Loading…
← CockpitCompetitor Analysis › 600351.SS Yabao Pharmaceutical Group Co. Ltd. Class AOpen in the cockpit ↗

Yabao Pharmaceutical Group Co. Ltd. Class A600351.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum leader 84
Mkt cap
$678M
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$30.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+12.1 pp
WACC 6.8%
Hurdle
-5 pp
Req g minus delivered
Close · CNYCN¥6.54
1D-1.1%
1W-5.8%
1M-5.3%
3M-7.1%
6M-0.1%
YTD+0.8%
1Y-3.5%
ATR %3.5%
52w lowhigh12.2% off high

What Yabao Pharmaceutical does

Employees: 3,415

Yabao Pharmaceutical at a glance

Size Yabao Pharmaceutical (600351.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $678M, the 2961st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.54 on 18 Nov 2026.

Performance Over six months the shares fell 0.1%, against -14.5% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue fell 3.5% over the last twelve months (peer median +7.1%); the operating margin is 15.6% (peer median 9.5%).

Valuation It trades at 1.6× enterprise value to sales against a peer median of 2.5× (6th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 12.1 points above its cost of capital (6.8% WACC).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026600351.SS 101Peer median 86
Six months, rebased to 100: Yabao Pharmaceutical against the median of its 20 peers (local-currency closes).

Yabao Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.19BCN¥2.22BCN¥2.67BCN¥2.89BCN¥2.70B
Revenue growth—-17%-8%+7%—
Gross profitCN¥1.25BCN¥1.11BCN¥1.31BCN¥1.60BCN¥1.43B
EBITDAn/aCN¥453MCN¥424MCN¥449MCN¥335M
Net incomeCN¥362MCN¥320MCN¥243MCN¥200MCN¥105M
Free cash flowCN¥613MCN¥529MCN¥440MCN¥398MCN¥403M
Capital expenditureCN¥33.9MCN¥48.9MCN¥34.7MCN¥99.9MCN¥62.2M
Total debtCN¥3.80MCN¥38.5MCN¥95.7MCN¥268MCN¥450M

Quarterly statements and history in the cockpit →

Yabao Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%-10%0%+10%688658PHIL688488ANNX0009154985SPARCNVCT600829FDCINNOVACAP453405700005663000166039984123SGMT600530600351.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Yabao Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%+3,000%0×5×10×15×688658PHIL6884880009154985SPARCINNOVACAP0005664123600530600351.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Yabao Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%6884884985600829FDCINNOVACAP3000166039984123600530600351.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Yabao Pharmaceutical is the large dot.

Yabao Pharmaceutical competitors and peer comparison

How Yabao Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Yabao Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600351.SSPeer medianRank in peer set
1-month return-5.3%-2.8%10th lowest of 21
6-month return-0.1%-14.5%7th highest of 21
Distance from 52-week high-12.2%-35.3%3rd highest of 21
Revenue growth (TTM)-3.5%+7.1%5th lowest of 18
Operating margin15.6%9.5%5th highest of 18
EV / Sales1.6×2.5×6th cheapest of 18
Growth the price implies (Req g, 7 yrs)-8.3%25.2%least demanding of 10
Growth delivered (Del g)-2.8%+7.9%lowest of 10
Hurdle (Req g minus delivered)-5.5 pp+1.2 pp2nd least demanding of 10
ROIC minus cost of capital+12.1 pp-0.3 pphighest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%1.6×-8.3%-2.8%
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%1.7×n/an/a
Philogen PHIL.MIItaly$672M-11%+295%79%0.9×n/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%6.7×31.9%+19.8%
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%2.5×n/an/a
Earth 4985.TJapan$687M+7%+4%4%0.5×-1.6%-1.8%
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%2.5×n/an/a
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%0.6×4.0%+5.3%
FDC FDC.NSIndia$653M+3%+10%14%2.4×25.2%+10.3%
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%3.4×27.1%+31.4%
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%0.8×n/an/a
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%0.3×n/an/a
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%10.6×n/an/a
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%3.0×9.1%+7.9%
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%2.6×-4.8%+6.4%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%3.9×n/an/a
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%16.1×42.7%-0.9%

Questions

Which companies are Yabao Pharmaceutical's closest peers?
The cockpit's peer set: Youcare Pharmaceutical (688658.SS), Philogen (PHIL.MI), Jiangsu Aidea Pharmaceutical (688488.SS), Annexon (ANNX), Shandong Wit Dyne Health (000915.SZ), Earth (4985.T), Sun Pharma Advanced Research (SPARC.NS), Nuvectis Pharma (NVCT).
Is Yabao Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 1.6× against a peer median of 2.5×, 6th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has Yabao Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -0.1% against -14.5% for the median peer; over one year -3.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.